UPDATE: Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program

NymoxPharmaceutical Corporation (Nasdaq: NYMX) is pleased to announce its lead drugcandidate, NX-1207, has not shown any evidence of eliciting an immune reactionin men treated with intraprostatic injections of the drug. Extensive clinicalimmunogenicity testing of men in the Company's pivotal Phase 3 trials(NX02-0017 and NX02-0018) and Phase 3 repeat injection safety study(NX02-0020) showed no evidence of antidrug antibody formation. Periodic safetymonitoring reviews of the NX-1207 trials to date have shown no evidence of anyallergic reaction to the drug either on first injection or repeat injection.Positive immunogenicity testing of NX-1207 is an important step in theCompany's drug development program. The results are consistent with thepharmacological and pharmacokinetic profile of the drug and augment theextensive safety experience with the drug in men with over 1,000 men havingreceived the drug to date.The Company will present more detailed scientific data from these studies atupcoming medical conferences. NX-1207 is in late stage Phase 3 development inthe U.S. for the treatment of benign prostatic hyperplasia (BPH), a commoncondition of older men associated with growth in prostate size as men age. TheCompany's NX02-0017 pivotal Phase 3 trial has completed enrollment. Phase 3trial activities of NX-1207 for BPH have begun in Europe sponsored byRecordati S.p.A., the company's European licensing partner. In the BPH studiesto date, a single dose of NX-1207 has been found to produce symptomaticimprovements about double that reported for currently approved BPH drugswithout causing the sexual or cardiovascular side effects associated withthose drugs.NX-1207 is also being evaluated for the treatment of low risk localizedprostate cancer where NX-1207 is administered directly into the area of theprostate where the cancer was detected. A U.S. Phase 2 study (NX03-0040) forthat indication is in progress.